drugset / Trial / NCT00509301
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus literally destroys the tumor "from the inside out." This may be an effective treatment for glioblastoma multiforme, a malignant type of brain cancer. PURPOSE: This trial is studying the safety and radiation distribution of Cotara® in patients with recurrent glioblastoma multiforme.
Timeline
- Start
- 2006-11
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 131-I-chTNT-1/B MAB | Monoclonal antibody | 1.5 unknown | Other |
| Subject | 131-I-chTNT-1/B MAB | Monoclonal antibody | 2 unknown | Other |
| Subject | 131-I-chTNT-1/B MAB | Monoclonal antibody | 2.5 unknown | Other |
| Subject | 131-I-chTNT-1/B MAB | Monoclonal antibody | 3 unknown | Other |